The founders of BioNTech, Uğur Şahin and Özlem Türeci, will leave the company to launch a new biotechnology venture focused on messenger RNA technology.

Novo Nordisk announced Tuesday that its experimental obesity treatment UBT251, a triple agonist targeting the GLP-1, GIP and glucagon receptors, delivered a statistically significant mean weight loss of up to 19.7% after 24 weeks in a clinical trial.